Investigating the potential molecular players and therapeutic drug molecules in carfilzomib resistant multiple myeloma by comprehensive bioinformatics analysis

References

• van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–427.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–567.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
   PubMed Web of Science ®Google Scholar
• Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412–5417.
   PubMed Web of Science ®Google Scholar
• Iida S. Mechanisms of action and resistance for multiple myeloma novel drug treatments. Int J Hematol. 2016;104(3):271–272.
   PubMed Web of Science ®Google Scholar
• Groen K, van de Donk N, Stege C, et al. Carfilzomib for relapsed and refractory multiple myeloma. Cancer Manag Res. 2019;11:2663–2675.
   PubMed Web of Science ®Google Scholar
• Bai Y, Su X. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma. Asia Pac J Clin Oncol. 2021;17(1):29–35.
   PubMed Web of Science ®Google Scholar
• Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–210.
   PubMed Web of Science ®Google Scholar
• Riz I, Hawley TS, Hawley RG. KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget. 2015;6(17):14814–14831.
   PubMedGoogle Scholar
• Riz I, Hawley TS, Marsal JW, et al. Noncanonical SQSTM1/p62–Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming. Oncotarget. 2016;7(41):66360–66385.
   PubMedGoogle Scholar
• Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613.
   PubMed Web of Science ®Google Scholar
• Almeida D, Azevedo V, Silva A, et al. PetriScape – a plugin for discrete Petri net simulations in Cytoscape. J Integr Bioinform. 2016;13(1):284.
   PubMedGoogle Scholar
• Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(Database issue):D945–D950.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
   PubMed Web of Science ®Google Scholar
• Tokar T, Pastrello C, Rossos AEM, et al. mirDIP 4.1-integrative database of human microRNA target predictions. Nucleic Acids Res. 2018;46(D1):D360–D370.
   PubMed Web of Science ®Google Scholar
• Han H, Cho JW, Lee S, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46(D1):D380–D386.
   PubMed Web of Science ®Google Scholar
• Fan Y, Siklenka K, Arora SK, et al. miRNet – dissecting miRNA-target interactions and functional associations through network-based visual analysis. Nucleic Acids Res. 2016;44(W1):W135–W141.
   PubMed Web of Science ®Google Scholar
• Cotto KC, Wagner AH, Feng Y-Y, et al. DGIdb 3.0: a redesign and expansion of the drug–gene interaction database. Nucleic Acids Res. 2018;46(D1):D1068–D1073.
   PubMedGoogle Scholar
• Servant N, Roméjon J, Gestraud P, et al. Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial. Front Genet. 2014;5:152.
   PubMed Web of Science ®Google Scholar
• Mohr S, Leikauf GD, Keith G, et al. Microarrays as cancer keys: an array of possibilities. J Clin Oncol. 2002;20(14):3165–3175.
   PubMed Web of Science ®Google Scholar
• Bilalis A, Pouliou E, Roussou M, et al. Increased expression of platelet derived growth factor receptor β on trephine biopsies correlates with advanced myeloma. J BUON. 2017;22(4):1032–1037.
   PubMed Web of Science ®Google Scholar
• Kumar S, Witzig TE, Timm M, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003;17(10):2025–2031.
   PubMed Web of Science ®Google Scholar
• van Andel H, Kocemba KA, Spaargaren M, et al. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia. 2019;33(5):1063–1075.
   PubMed Web of Science ®Google Scholar
• Stelzl U, Worm U, Lalowski M, et al. A human protein–protein interaction network: a resource for annotating the proteome. Cell. 2005;122(6):957–968.
   PubMed Web of Science ®Google Scholar
• Sewify EM, Afifi OA, Mosad E, et al. Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression. Clin Lymphoma Myeloma Leuk. 2014;14(3):215–222.
   PubMed Web of Science ®Google Scholar
• Cook JR, Hsi ED, Worley S, et al. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol. 2006;125(4):615–624.
   PubMed Web of Science ®Google Scholar
• Lehn S, Tobin NP, Berglund P, et al. Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. Am J Pathol. 2010;177(6):2886–2897.
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Baladandayuthapani V, Lin HY, et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014;28(2):373–383.
   PubMed Web of Science ®Google Scholar
• Saltarella I, Frassanito MA, Lamanuzzi A, et al. Homotypic and heterotypic activation of the notch pathway in multiple myeloma-enhanced angiogenesis: a novel therapeutic target? Neoplasia. 2019;21(1):93–105.
   PubMed Web of Science ®Google Scholar
• Muguruma Y, Yahata T, Warita T, et al. Jagged1-induced notch activation contributes to the acquisition of bortezomib resistance in myeloma cells. Blood Cancer J. 2017;7(12):650.
   PubMedGoogle Scholar
• Hudlebusch HR, Theilgaard-Mönch K, Lodahl M, et al. Identification of ID-1 as a potential target gene of MMSET in multiple myeloma. Br J Haematol. 2005;130(5):700–708.
   PubMed Web of Science ®Google Scholar
• Grcević D, Kusec R, Kovacić N, et al. Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. Leuk Res. 2010;34(6):742–751.
   PubMed Web of Science ®Google Scholar
• Sukhdeo K, Mani M, Zhang Y, et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A. 2007;104(18):7516–7521.
   PubMed Web of Science ®Google Scholar
• Derksen PW, Tjin E, Meijer HP, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A. 2004;101(16):6122–6127.
   PubMed Web of Science ®Google Scholar
• Tagde A, Rajabi H, Bouillez A, et al. MUC1-C drives MYC in multiple myeloma. Blood. 2016;127(21):2587–2597.
   PubMed Web of Science ®Google Scholar
• Arumugam K, Shin W, Schiavone V, et al. The master regulator protein BAZ2B can reprogram human hematopoietic lineage-committed progenitors into a multipotent state. Cell Rep. 2020;33(10):108474.
   PubMed Web of Science ®Google Scholar
• Drouin L, McGrath S, Vidler LR, et al. Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. J Med Chem. 2015;58(5):2553–2559.
   PubMed Web of Science ®Google Scholar
• Courson DS, Cheney RE. Myosin-X and disease. Exp Cell Res. 2015;334(1):10–15.
   PubMed Web of Science ®Google Scholar
• Wang J, Li Z, Yin F, et al. Glioma pathogenesis-related protein 1 performs dual functions in tumor cells. Cancer Gene Ther. 2022;29(3–4):253–263.
   PubMed Web of Science ®Google Scholar
• Friend N, Noll JE, Opperman KS, et al. GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. PLOS One. 2020;15(1):e0228408.
   PubMed Web of Science ®Google Scholar
• Kikuchi J, Hori M, Iha H, et al. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia. 2020;34(1):180–195.
   PubMed Web of Science ®Google Scholar
• D'Aniello C, Patriarca EJ, Phang JM, et al. Proline metabolism in tumor growth and metastatic progression. Front Oncol. 2020;10:776.
   PubMed Web of Science ®Google Scholar
• Deng M, Zhang W, Yuan L, et al. HIF-1a regulates hypoxia-induced autophagy via translocation of ANKRD37 in colon cancer. Exp Cell Res. 2020;395(1):112175.
   PubMed Web of Science ®Google Scholar
• Chen X, Liu Y, Yang Z, et al. LINC01234 promotes multiple myeloma progression by regulating miR-124-3p/GRB2 axis. Am J Transl Res. 2019;11(10):6600–6618.
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu H, Fang C, et al. Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma. Cancer Res. 2020;80(10):2031–2044.
   PubMed Web of Science ®Google Scholar
• Čepulytė R, Žučenka A, Pečeliūnas V. Combination of dabrafenib and trametinib for the treatment of relapsed and refractory multiple myeloma harboring BRAF V600E mutation. Case Rep Hematol. 2020;2020:8894031.
   PubMed Web of Science ®Google Scholar
• Raje N, Chau I, Hyman DM, et al. Vemurafenib in patients with relapsed refractory multiple myeloma harboring BRAFV600 mutations: a cohort of the histology-independent VE-BASKET study. J Clin Oncol Precis Oncol. 2018;2(2):1–9.
   Google Scholar
• Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401–2409.
   PubMed Web of Science ®Google Scholar